| Prenylated xanthones |
|
|
Increased lipophilicity |
216
|
|
Improved solubility |
| Tetraoxygenated xanthones |
|
|
Wider spectrum, more selective antibacterial activity |
42 and 218
|
|
Lower toxicity; antibacterial activity |
42 and 219
|
| Wider spectrum, antifungal activity |
|
Rapid bactericidal effect |
220
|
| Lower toxicity |
| Avoidance of induced resistance |
| Higher selectivity |
|
Rapid bactericidal effect |
220
|
| Lower toxicity |
| Avoidance of induced resistance |
| Higher selectivity |
|
Higher solubility |
69
|
|
Higher antiangiogenic and anticancer activities |
69
|
| Higher bioavailability |
| Miscellaneous xanthones |
|
|
Higher potency |
193
|
|
Higher potency |
193
|
|
Higher potency |
193
|
| Prenylated xanthones |
|
|
Higher potency |
197
|
| Higher selectivity |
|
Higher potency |
197
|
| Higher selectivity |
|
|
Higher potency |
198 and 199
|
| Higher selectivity |
| Xanthone glycoside |
|
|
Higher lipid solubility |
211
|
| Better bioavailability |
| More potent hypoglycemic effect |
|
Higher lipid solubility |
211
|
| Better bioavailability |
| More potent hypoglycemic effect |
|
Higher lipid solubility |
211
|
| Better bioavailability |
| More potent hypoglycemic effect |
|
Better solubility and bioavailability |
214, 215 and 221
|
| Broader biological effects |
|
Better solubility and bioavailability |
221
|
| More potent antitussive effect |